Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Mesothelioma
Interventions
DRUG

Durvalumab / tremelimumab

"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."

DRUG

Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab

"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."

Trial Locations (2)

27710

NOT_YET_RECRUITING

Duke Cancer Institute, Durham

77030

RECRUITING

Baylor St Lukes, Houston

All Listed Sponsors
collaborator

Duke Cancer Institute

OTHER

lead

Baylor College of Medicine

OTHER